Overview
- Yahoo Finance highlights CRISPR Therapeutics as a company worth about $5 billion whose long-term case centers on its gene-editing pipeline.
- CTX310 aims to switch off the ANGPTL3 gene to lower LDL cholesterol and triglycerides, with the goal of a one-time dose for high-risk patients.
- CRISPR Therapeutics cites roughly 40 million people in the U.S. with high LDL or triglycerides, so a 0.1% share would mean about 40,000 treatments.
- CTX320 targets lipoprotein(a), a blood particle tied to heart attacks and strokes, and is also described as a potential single-dose option.
- Near-term income remains light as Casgevy, its only approved therapy, faces manufacturing hurdles, while rival Lyfgenia recorded more than 100 infusions last year.